Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $13.50.
Several research firms recently issued reports on NKTX. Stifel Nicolaus cut their price target on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Wall Street Zen downgraded Nkarta from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Nkarta in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th.
Check Out Our Latest Analysis on NKTX
Hedge Funds Weigh In On Nkarta
Nkarta Price Performance
Nkarta stock opened at $2.63 on Monday. Nkarta has a 12 month low of $1.31 and a 12 month high of $4.55. The business has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $1.96. The stock has a market capitalization of $186.81 million, a PE ratio of -1.78 and a beta of 0.86.
Nkarta (NASDAQ:NKTX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. As a group, equities research analysts anticipate that Nkarta will post -1.7 EPS for the current year.
About Nkarta
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Read More
- Five stocks we like better than Nkarta
- The Role Economic Reports Play in a Successful Investment Strategy
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Most active stocks: Dollar volume vs share volume
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Investing in Construction Stocks
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.